Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 31.4% during trading on Monday . The company traded as low as GBX 6.70 and last traded at GBX 6.70. 27,337,178 shares were traded during mid-day trading, an increase of 242% from the average session volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Stock Down 31.4%
The firm has a market cap of £33.68 million, a P/E ratio of -7.53 and a beta of 1.53. The firm’s fifty day moving average is GBX 10.96 and its two-hundred day moving average is GBX 5.84.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Basic Materials Stocks Investing
- D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
- Using the MarketBeat Dividend Tax Calculator
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
